LENZ Therapeutics (LENZ)

• Market cap: $897M
• 1 day: 7.76%
• 5 days: 5.39%
• 1 month: -3.77%
• 3 months: 45.73%
• 6 months: 80.68%
• Year to date: 101.42%
• 1 year: 101.42%
• 5 years: 101.42%
• 10 years: 101.42%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

130% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 10

36% more capital invested

Capital invested by funds: $328M [Q2] → $445M (+$117M) [Q3]

25% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 16

20% more funds holding

Funds holding: 65 [Q2] → 78 (+13) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q2] → 4 (+0) [Q3]

6.21% less ownership

Funds ownership: 74.34% [Q2] → 68.13% (-6.21%) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $37 13% upside
• Avg. target: $38 15% upside
• High target: $38 16% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Matthew Caufield 24% 1-year accuracy 12 / 50 met price target	16% upside $38	Buy Reiterated	7 Nov 2024
Raymond James Gary Nachman 54% 1-year accuracy 7 / 13 met price target	13% upside $37	Outperform Initiated	27 Sept 2024